tems described by Rai et al. [24] and Binet et al. [1] are useful methods for assessing patient prognosis, they do not permit to understand the basis of this heterogeneity. In the last decade, it has been demonstrated that the immunoglobulin (Ig) VH gene mutational status predicts the natural history of the disease. Indeed, the presence of unmutated (UM) VH genes was highly associated with a much poorer prognosis. Median survival in patients whose CLL cells express UM IGHV genes ranges between 60 and 119 months. In contrast, patients whose CLL cells express mutated (M) IGHV genes have a distinctly longer median survival and many may never require treatment. It is now admitted that an UM germ line configuration of the IGHV genes constitutes a crucial adverse prognostic factor in CLL under conventional chemotherapy treatment as well as after autologous stem cell transplantation [6, 11, 16, 22] . Several other prognostic factors have been described in CLL, including cytogenetic abnormalities [8] , ZAP-70 expression [5] , CD38 expression [6] , serum markers such as soluble CD23 [26] , thymidine kinase [10] and β 2 -microglobulin [13] . Our group has suggested that expression of lipoprotein lipase (LPL) and a disintegrin and metalloproteinase domain 29 (ADAM29) genes are closely correlated to IGHV mutational status with a concordance rate of 82% for ADAM29 gene and M status and 76% for LPL gene and UM status. Interestingly, the value of the LPL/ADAM29 ratio as well as LPL/ADAM29 expression assessed by a qualitative multiplex polymerase chain reaction (PCR) improves this correlation with a concordance rate of 90%. Both have been described to be very good prognostic factors associated with event-free survival and overall survival [21] . Until now, few studies were devoted to the impact of prognostic factors on the treatment response and disease-free survival (DFS). Byrd et al. [2] showed that although no correlation was observed between IGHV mutational status and cytogenetic aberrations with treatment response, these prognostic factors were both highly correlated to DFS in CLL patients in complete remission (CR) after treatment with rituximab, fludarabine and cyclophosphamide combination. More recently, the same group showed that interphase cytogenetic analysis, but not IGHV, CD38 expression or ZAP-70 status, can predict the outcome of fludarabine-based chemotherapy and that patients with high-risk cytogenetic features should be considered for alternative therapies [9] .Very recently, Laurenti et al. [14] reported that oral fludarabine + cyclophosphamide could be an appropriate treatment in CLL patients with low-risk biological parameters. They showed that a shorter PFS and a shorter time to retreatment (TTR) were observed in patients with "high-risk" cytogenetic abnormalities. They also showed that patients with UM IGHV displayed shorter TTR when compared to M cases. No study has analysed yet the impact of LPL and ADAM29 gene expression on the clinical outcome for patients in CR. Minimal residual disease (MRD) status has been shown to be a good clinical outcome predictor, since patients who achieved complete phenotypic remission as assessed by four-colour flow cytometry in the blood and/or in the bone marrow had a superior response duration and survival when compared with patients who were MRD + [15, 18, 25, 29] . Our results confirm the importance of MRD assessment as a good clinical outcome predictor and demonstrate the impact of IGHV mutational status and LPL/ ADAM29 gene expression on DFS and OS in CLL patients in response following oral fludarabine + cyclophosphamide.
Materials and methods

Patients
Among the 75 progressive CLL patients treated by first-line oral fludarabine + cyclophosphamide recently reported by Cazin et al. [3] , 41 were included in this study, of whom 38 were in CR and three in nodular partial remission (nPR; n=3) according to the NCI criteria [4] .
IGHV mutational status
The IGHV gene sequences were determined as previously described [23] . Briefly, amplification of immunoglobulin heavy chain variable regions by PCR was performed on DNA from leukaemic cells with consensus primers for the VH framework region 1 and JH genes or following the BIOMED-2 protocols. Purified PCR products were sequenced either directly or after a cloning procedure using an automated DNA sequencer. Sequence data were analysed using IgBLAST (http://www.ncbi.nlm.nih.gov/ igblast) and the ImMunoGeneTics database (IMGT; http:// imgt.cines.fr). IGHV sequences were considered as M if their homology with the closest germ line counterpart was less than 98%.
LPL and ADAM29 gene expression
We have previously demonstrated that the qualitative multiplex-PCR method is simple and as reliable as the quantitative RQ-PCR for the LPL/ADAM29 gene expression in CLL patients. In the present study, we evaluated the relative expression of LPL and ADAM29 gene by multiplex reverse transcriptase PCR, by using primers designed with the Oligo 6 software (Table 1) . These primers were validated by performing this PCR on 33 known samples previously quantified by RQ-PCR [21] . Total cellular RNA was extracted and its integrity was assessed by visualisation of the 18S and 28S RNA species on electrophoresis in agarose gel after ethidium bromide staining. First-strand complementary DNA (cDNA) was synthesised from 2 µg total RNA using Superscript II reverse transcriptase (Invitrogen, Cergy-Pontoise, France) and oligodT or random hexamer primers. Optimised PCR conditions were obtained with primers at the final concentrations of 0.5 µM, 1.5 mM MgCl 2 and 200 µM dNTP. Amplifications were performed on 60 ng cDNA and included an initial denaturation step at 94°C for 4 min, followed by 29 cycles of 30 s at 94°C, 30 s at 58°C and 30 s at 72°C. Finally, the reaction was completed with a final elongation step at 72°C for 5 min. PCR products were analysed on ethidiumbromide-stained 11% acrylamide gel electrophoresis where they appeared as a 130-bp band for ADAM29 and a 110-bp band for LPL (Fig. 1) . Amplification of ABL was performed in parallel to ensure cDNA integrity.
MRD assessment
Two months after the treatment ended, blood flow cytometry (FC) analysis was carried out in order to detect residual leukaemic cells in the blood as previously described [17] . Briefly, we used a four-colour FC with a panel of antibodies including anti-CD19, anti-CD20, anti-CD5, anti-CD79b antibodies and a Becton Dickinson FACScalibur device (San Jose, CA, USA). The sensitivity of this FC technique was of 10 −4 .
Statistical analysis
Survival analyses were performed using the Kaplan-Meier method. Statistical significance of associations between individual variables and survival was calculated by the logrank test. These analyses were performed using MedCalc® Version 9.3.0.0 (http://www.medcalc.be).
Results
Clinical characteristics
Forty-one advanced CLL (Binet stage B or C) patients achieving remission after treatment with oral fludarabine plus cyclophosphamide were enrolled in this study. Thirtyeight were in CR and three in nPR according to NCI criteria [4] . Fig. 2c ). Although the median survival was not reached, six out of 18 LPL patients died at 16, 25, 41, 45, 53 and 57 months, whilst no death was observed in the group of ADAM29-expressing patients (p= 0.01; Fig. 2d ) [21] . Interestingly, three discordant cases regarding LPL and ADAM29 expression vs mutational status were observed with ADAM29 overexpression and UM IGHV. Among them, two patients achieved phenotypic MRD and clinical outcome MRD evaluation in the blood was performed 2 months after the end of the treatment in 33 out of the 41 patients. Among these 33 patients, 21 achieved phenotypic remission at the time of the treatment evaluation, of whom 13 were still in remission with a median time follow-up of 66 (53-68) months, and the remaining eight patients relapsed at a median time of 44 (22-56) months. In the group of the 12 MRD + patients, ten relapsed at a median time of 28 (3-60) months. As shown in Fig. 2e , patients achieving phenotypic remission displayed longer DFS (p=0.0009). However, no significant difference was observed regarding OS (Fig. 2f) . Interestingly, among the 13 patients expressing M VH genes, ten achieved phenotypic remission (77%). In contrast, 11 out of 20 patients with UM VH genes achieved phenotypic remission (55%). Although there is a tendency of a higher rate of phenotypic remission in the group of M patients when compared with UM patients, the difference is not statistically significant (p=0.2). When regarding LPL and ADAM29 gene expression and MRD, the results are similar to those observed with the mutational status and showed that 11 of 18 MRD − patients expressed ADAM29, whilst eight of 11 MRD + patients expressed LPL (p=0.07). Data are visualised in Table 2 .
Discussion
In this work, we have described a series of CLL patients in clinical remission after oral fludarabine plus cyclophosphamide, for whom we have assessed the recently described prognostic factors, including IGHV mutational status and LPL/ADAM29 gene expression and, for some of them, interphase cytogenetics. Furthermore, we looked at the predictive value of MRD status at the time of the treatment evaluation for relapse and OS. The influence of IGHV mutational status and cytogenetic abnormalities on time to treatment from initial CLL diagnosis and OS has been demonstrated by previous studies [6, 11] . Our group has shown that LPL and ADAM29 gene expression is closely correlated to IGHV gene mutational status. Indeed, in a series of 119 CLL patients, LPL gene showed a concordance rate of 76% with UM IGHV status and for ADAM29 gene a concordance rate of 82% with M profile. Interestingly, the correlation was higher when using LPL/ADAM29 ratio with a concordance rate of 90%. Furthermore, LPL and ADAM29 gene expression appeared to be a strong prognostic factor for event-free survival and OS [21] . Other reports have confirmed the prognostic value of LPL expression gene in CLL [12, 19, 20, 27, 28] . In contrast, very few studies have looked at the impact of these prognostic factors on the clinical outcome of the CLL patients in remission after treatment. In a recent report by Byrd et al. [2] , IGHV UM status and high-risk interphase cytogenetics, including del(17p) or del(11q), predict statistically inferior DFS and OS in patients in CR after chemoimmunotherapy. Herein, we have shown that patients with M IGHV genes had longer DFS and OS when compared to UM patients. The expression of LPL and ADAM29 genes is correlated to the VH mutational status, since all LPL-expressing patients have UM VH genes and the majority of ADAM29-expressing patients have M VH genes. Furthermore, patients with MRD-negative displayed significant longer DFS than those with persistent leukaemic cells in the blood. However no significant difference in term of OS was observed when comparing MRD + patients with MRD − patients. More recently, Laurenti et al. [14] showed that the oral combination of fludarabine and cyclophosphamide was an effective and well-tolerated regimen and that a shorter TTR was observed in IGHV UM cases when compared to M ones (p=0.035). We recently showed the high efficacy of this combination in 75 pre-untreated CLL patients with a very high overall response (80%) and CR (53%) [3] . Herein, we analysed the IGHV mutational status and LPL/ADAM29 expression in 41 remitters among the 75 patients of this series. We showed that the UM cases represented 61% and M cases 39% as expected in progressive CLL. In addition, the IGHV usage corresponded to classical distribution displaying an overrepresentation of VH3 and VH1 genes, particularly VH1-69 gene [22] . Regarding OS according to mutational status, the M group had longer OS since all of them were still alive at the endpoint time with a median follow-up of 64 months. This is in agreement with previous reports which looked at the influence of this parameter on survival from initial CLL diagnosis [6, 11, 16, 22] . Concerning DFS, among the 21 cases who relapsed, 16 expressed UM VH genes and only five expressed M VH genes (p=0.01). These results are in agreement with those reported by Byrd et al. [2] who showed that M patients displayed longer DFS and OS and those of Laurenti et al. [14] showing a shorter TTR in UM patients. Similarly, we looked at the impact of LPL and ADAM29 expression on the clinical outcome of these responder patients, showing that LPL-expressing patients display shorter DFS and OS since 14 of the 18 cases relapsed with a median TTP of 32 months, whilst only six out of the 17 ADAM29 cases relapsed with a median TTP of 28 months. We have also confirmed that LPL and ADAM29 expression could be a surrogate of IGHV mutational status, as previously described [21] . Of note is that the three discordant cases with overexpression of ADAM29 and UM IGHV were still alive at 58, 66 and 70 months, and two of them did not relapse. Altogether, these results suggest that mutational status as well as LPL and ADAM29 gene expression represent important outcome predictive factors not only from initial diagnosis as previously described [21] but also in CLL patients in remission after chemotherapy. In addition, our work confirms the high interest of MRD evaluation in CLL patients since we found a good correlation between MRD status and DFS as previously described [15, 18, 25, 29] . In this series, the achievement of phenotypic remission was slightly higher in the group of patients with M VH genes and ADAM29 gene expression when compared with UM and LPL-expressing patients. However, the difference was not statistically significant, and it will be interesting to verify this result on a larger series. These data strongly suggest that LPL and ADAM29 gene expression associated to IGHV mutational status could be helpful in adapting treatment modalities. Further studies are needed to confirm the prognostic interest of these markers used in combination for outcome prediction after different treatment strategies. Patients expressing ADAM29 and M IGHV achieved more frequently phenotypic remission than those expressing LPL and UM IGHV M mutated, UM unmutated
